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ABSTRACT 21 
Despite influencing many aspects of T cell biology, the kinetics of T cell receptor (TCR) 22 
binding to peptide-major histocompatibility molecules (pMHC) remain infrequently 23 
determined in patient monitoring or for adoptive T cell therapy. Using specifically designed 24 
reversible fluorescent pMHC multimeric complexes, we performed a comprehensive study of 25 
TCR-pMHC off-rates combined with various functional assays on large libraries of 26 
self/tumor- and virus-specific CD8 T cell clones from melanoma patients and healthy donors. 27 
We demonstrate that monomeric TCR-pMHC dissociation rates accurately predict the extent 28 
of cytotoxicity, cytokine production, polyfunctionality, cell proliferation, 29 
activating/inhibitory receptor expression and in vivo anti-tumor potency of naturally 30 
occurring antigen-specific CD8 T cells. Our data also confirm the superior binding avidities 31 
of virus-specific T cells as compared to self/tumor-specific T cell clonotypes (n > 300). 32 
Importantly, the TCR-pMHC off-rate is a more stable and robust biomarker of CD8 T cell 33 
potency, than the frequently used functional assays/metrics that depend on the T cell’s 34 
activation state and therefore show major intra- and inter-experimental variability. Together, 35 
the monomeric TCR-pMHC off-rate is highly useful for the ex vivo high throughput 36 
functional assessment of antigen-specific CD8 T cell responses and a strong candidate as a 37 
biomarker of T cell therapeutic efficacy.  38 
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INTRODUCTION 39 
Cytotoxic T lymphocytes mediate immune protection against a large number of infectious 40 
diseases, and recent developments in oncology confirmed their ability to eliminate cancers. 41 
To achieve successful immunity, T cells must be activated through specific interactions 42 
between T cell receptors (TCR) and antigenic peptides presented by major histocompatibility 43 
molecules (pMHC) on antigen-presenting cells. This enables T cell expansion and 44 
differentiation into large numbers of effector cells with various functional capacities (i.e. 45 
killing, cytokine production, proliferation). Furthermore, T cells must migrate and localize to 46 
the infected or tumoral tissues, exerting their effector function and finally acquire memory 47 
properties, assuring long-lasting immunity.  48 
Extensive research has been undertaken to determine which T cell properties are essential to 49 
generate protective and durable immune responses. T cell functional avidity, which measures 50 
in vitro T cell responses when exposed to increasing antigen concentrations, has been largely 51 
associated with the control of viral (1-3) or tumor (4, 5) load in animal models. In accordance 52 
with these observations, several findings in patients with HIV (6, 7) or hepatitis C (8, 9) 53 
infections further showed the key role of CD8 T cells of high functional avidity in efficient 54 
viral control and clearance. Yet, others have challenged the functional superiority of such 55 
high-avidity cells, which may be prone to increased activation-induced cell death, senescence 56 
or exhaustion (reviewed in (10)). In the context of anti-tumor responses, results obtained 57 
from melanoma patients also indicate that T cells of high functional avidities are required for 58 
efficient protection (11-13). Besides functional avidity, higher proportions of polyfunctional 59 
CD8 or CD4 T cells were also found in HIV (14, 15) and hepatitis C (16) controllers, when 60 
compared to individuals with progressive disease. Moreover, some reports proposed a direct 61 
link between functional avidity (i.e. antigen sensitivity) and polyfunctionality (i.e. T cell 62 
capacity to exert multiple effector functions) (17, 18). However, the ex vivo appraisal of T 63 
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cell functionality/polyfunctionality is still often limited to assays of fixed stimulation doses 64 
and by the lack of universal standards of T cell assessment (reviewed in (19, 20)). It is 65 
therefore essential to improve our knowledge regarding the contribution of the different 66 
aspects of T cell function to clinical efficacy and to identify additional T cell-based 67 
parameters that may enable overcoming some of the limitations associated to functional 68 
assays.   69 
The functional avidity of T cells is primarily controlled by the strength of TCR-pMHC 70 
interactions, a key parameter shown to impact on numerous aspects of T cell biology, 71 
including their thymic selection (21), activation and differentiation (22), autoimmune 72 
pathogenicity (23), and protection against infection and cancer (24). In fact, TCR-pMHC 73 
binding avidity may offer a key metric by which the quality of the T cell response can be 74 
directly evaluated, since it controls T cell activation, differentiation and functional efficacy 75 
(25). Numerous studies indicate, that within the affinity range of physiological interactions 76 
(KD 100 - 1 µM), enhanced TCR-pMHC affinity or off-rate (koff) correlate with improved T 77 
cell functionality (26). However, most of these reports are based on artificial models (e.g. 78 
using affinity-optimized TCR variant panels or altered peptide ligand models), and thus only 79 
limited information is available on the overall impact and clinical relevance of TCR-pMHC 80 
binding avidity or kinetics (e.g. off-rates) in the context of naturally occurring antigen-81 
specific CD8 T cell responses. Moreover, identifying and selecting TCRs of higher avidity 82 
may be of particular importance in the tumoral setting, since most high avidity/affinity 83 
self/tumor antigen-reactive T cells are naturally eliminated or silenced by mechanisms of 84 
central and peripheral tolerance, emphasizing the need to select the remaining rare high 85 
avidity cells for immunotherapy. 86 
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Reversible two-color multimer-based approaches (i.e. Streptamers, NTAmers) have been 87 
developed to precisely quantify monomeric TCR-pMHC dissociation rates (i.e. off-rate or 88 
koff) directly on living T cells. Streptamers initially revealed that virus-specific CD8 T cells 89 
with longer off-rates conferred better in vivo protection than T cells with shorter off-rates 90 
(27). However, owing to the faster decay of the multimeric complex onto monomeric pMHC 91 
when compared with Streptamers, NTAmers offer an increased sensitivity to detect T cells of 92 
low avidity TCRs (26), such as those typically found in self/tumor-specific CD8 T cell 93 
repertoires. Consequently, we recently showed that NTAmer-based koff  strongly correlated 94 
with the killing capacity of TCR-engineered and natural tumor-specific human CD8 T cells 95 
(28, 29). 96 
With the aim to thoroughly evaluate possible correlations between T cell function and TCR-97 
pMHC binding kinetics, we here undertook a large-scale analysis of combined multiple 98 
functions (i.e. killing, CD107a degranulation, cytokine production, proliferation, surface 99 
expression of activating/inhibitory receptors and tumor control) and optimized off-rate 100 
measurements using NTAmers to characterize large libraries of tumor- and virus-specific 101 
CD8 T-cell clones isolated from melanoma patients and healthy donors. Our large data sets 102 
show that the TCR-pMHC off-rate is a major determinant controlling the functions of CD8 T 103 
cells in vitro and in vivo. Our findings are also of practical importance, as we found that the 104 
TCR-ligand dissociation rate is a highly stable biomarker, more reliable and reproducible 105 
than the usual assessments based on multimer staining levels or functional T cell avidity, 106 
which may fluctuate depending on the T cell’s activation state.  107 
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RESULTS 108 
TCR-pMHC off-rate accurately correlates to overall T cell functional avidity 109 
To precisely address the relationship between the TCR-pMHC off-rate and the overall CD8 T 110 
cell functional profile, we generated large libraries of HLA-A*0201-restricted CD8 T cell 111 
clones, by direct ex vivo sorting and cloning of self/tumor-specific (i.e. Melan-A26-35 and 112 
NY-ESO-1157-165) and virus-specific (i.e. Cytomegalovirus CMV/pp65495-504 and Epstein-Barr 113 
virus EBV/BMFL1259-267) effector-memory (EM) T cells (Supplemental Figure 1). We 114 
analyzed all clones for TCR-pMHC dissociation rates using NTAmers loaded with the native 115 
Melan-A, NY-ESO-1, EBV/BMFL1 or CMV/pp65 peptide because they provided a more 116 
physiological assessment of the TCR-pMHC recognition efficacy as opposed to the 117 
corresponding analog peptides (as detailed in Methods). Representative koff-based panels of 118 
self/tumor- and virus-specific CD8 T cell clones were further characterized at the functional 119 
level, including assessment of cytotoxic activity, CD107a degranulation, and production of 120 
cytokines based on peptide titration assays, as well as proliferation (Supplemental Figure 2). 121 
Note that, for the same antigen-specificity, most of the different functional readouts/measures 122 
were obtained during the same non-specific restimulation cycle to make use of the antigen-123 
specific CD8 T cell clones in a similar resting state (>D15 post restimulation).  124 
We observed, for all antigenic specificities, statistically significant correlations between 125 
TCR-pMHC off-rates and various functional avidity readouts (EC50, defined as the peptide 126 
concentration producing half-maximal response) or proliferative capacity (% of divided cells) 127 
(Figure 1 and Supplemental Figure 3, A and B). Yet, stronger correlations (p < 0.01-0.001, 128 
r > 0.5 and narrow confidential intervals) were generally found for self/tumor- (Melan-A and 129 
NY-ESO-1) than non-self/virus- (CMV/pp65 and EBV/BMFL1) specific T cells. By contrast, 130 
no positive correlations could be observed between TCR-pMHC off-rates and the maximally 131 
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reached functions at saturating peptide doses (Bmax, maximal response) (Supplemental 132 
Figure 3C; data not shown). In turn, the maximal response depended on the in vivo 133 
differentiation status, with stronger Th2-related cytokine production by clones derived from 134 
the early-differentiated EM/CD28+ cells and greater granzyme B expression and killing by 135 
those from the late-differentiated EM/CD28- cells (Supplemental Figure 3D). Collectively, 136 
these results indicate that, within an antigen-specific repertoire, the kinetics of TCR-pMHC 137 
interactions represent a major determinant of the overall functional avidity of CD8 T cells, 138 
regardless of their differentiation status (Supplemental Figure 3D) or function-specific 139 
activation thresholds (killing < CD107a < interferon-gamma (IFNγ) < tumor-necrosis factor 140 
alpha (TNFα) < IL-2) (Supplemental Figure 4A). 141 
  142 
TCR-pMHC off-rate closely correlates to CD8 T cell polyfunctionality 143 
Protective immunity against intracellular pathogens relies on the individual CD8 T cell 144 
capacity to display multiple effector functions or polyfunctionality (10). We hypothesized 145 
that the kinetics of TCR-pMHC interactions could also affect their polyfunctionality. The co-146 
expression levels of CD107a, IFNγ, TNFα and IL-2 were characterized on a representative 147 
selection of self/tumor- and virus-specific CD8 T cell clones with relative slow or fast TCR-148 
pMHC off-rates (Figure 2). For all antigenic specificities and peptide titrations tested, the 149 
fraction of cells displaying more than one single function was always greater in CD8 T cell 150 
clones with slower TCR-pMHC off-rates than with faster ones (Figure 2A). In line with 151 
these observations, we found that a significant proportion of antigen-specific CD8 T cell 152 
clones with slow TCR-pMHC off-rates showed increased polyfunctional capacities (in terms 153 
of EC50 titration curves) when compared to the clones of fast TCR-pMHC off-rates (Figure 154 
2, B-D). However, a strict correlation between off-rates and polyfunctionality was not always 155 
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found, and limited differences were mostly observed in the EBV-specific CD8 T cell 156 
responses. Taken together, the TCR-pMHC off-rate not only predicts single functional 157 
avidities of self/tumor- and virus-specific CD8 T cells, but also their capacity to co-develop 158 
multiple effector functions.  159 
 160 
TCR-pMHC off-rate closely follows co-stimulatory/-inhibitory receptor expression in 161 
activated CD8 T cells 162 
PD-1 surface expression on CD8 T cells has been reported to positively correlate with TCR-163 
pMHC binding avidity (30) or functional avidity (31). Here, we explored the relationship 164 
between NTAmer-derived off-rates and the expression of various co-stimulatory (CD28 and 165 
CD137) and co-inhibitory (LAG-3, PD-1, TIGIT and TIM-3) receptors (Figure 3). No 166 
consistent correlations were found when CD8 T cell clones were assessed in a resting state 167 
(data not shown). In contrast, following 24 hours of stimulation with self/tumor or viral 168 
peptides, we observed substantial correlations between TCR-pMHC off-rates and the extent 169 
of increased expression of both co-stimulatory and -inhibitory receptors (Figure 3, A-F). 170 
These data indicate a direct impact of TCR-pMHC binding avidities on the susceptibility of 171 
CD8 T cells to antigen-specific activation, and consequently on the up-modulation of both 172 
co-stimulatory and -inhibitory receptors upon stimulation. 173 
We also investigated whether TCR-pMHC off-rates associated with CD5 expression, which 174 
is a measure of the strength for self-pMHC selecting ligands during thymocyte development 175 
(32). At baseline, most virus-specific CD8 T cell clones displayed high expression levels of 176 
CD5, irrespective of their TCR-pMHC off-rates (Figure 3G). These data are in line with 177 
previous reports proposing that T cells with greater TCR’s sensitivity to self pMHC are most 178 
efficiently recruited in response to foreign antigens (33, 34). Positive correlations were only 179 
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found in the context of self/tumor-specific CD8 T cell clones, with slower off-rates 180 
associating to higher baseline levels of CD5 (Figure 3G and Supplemental Figure 5). This 181 
latter observation suggest that the expression levels of CD5 on self/tumor-specific T cells 182 
may also predict their capacity for increased homeostatic or antigen-specific response. 183 
 184 
TCR-pMHC off-rate predicts the in vivo functional potency of self/tumor-specific CD8 185 
T cells 186 
To further substantiate the relevance of our in vitro observations, we evaluated the impact of 187 
TCR-pMHC off-rates on the ability of self/tumor-specific CD8 T cells to control tumor 188 
growth in vivo. We first adoptively transferred A2/Melan-A26-35-specific CD8 T cell clones 189 
of slow versus fast TCR-pMHC off-rates into immunodeficient NSG mice bearing human 190 
melanoma Me275 tumors (Figure 4A). The transfer of fast off-rate T cell clones showed 191 
intermediate tumor growth control. In contrast, T cell clones of slow off-rates mediated a 192 
more significant delay in tumor growth when compared to the untreated (PBS) group (Figure 193 
4B). Furthermore, a significantly prolonged survival was only observed for mice treated with 194 
A2/Melan-A26-35-specific clones of slow TCR-pMHC off-rates (Figure 4C). To confirm 195 
those observations, we then performed similar experiments using the A2/NY-ESO-1 196 
antigenic model, but this time, all mice received s.c. injections of human recombinant IL-2 to 197 
enhance the T cell anti-tumor efficacy (Figure 4D). In line with the observations made on 198 
Melan-A26-35-specific T cells, NY-ESO-1157-165-specific CD8 T cell clones of slow TCR-199 
pMHC off-rates provided a significant delay in tumor growth in comparison to the clones 200 
with fast off-rates (Figure 4E). Finally, we monitored the peripheral persistence of NY-ESO-201 
1-specific T cells at days 2 and 14 following adoptive transfer. Analysis of tail bleeds taken at 202 
day 2 revealed that there was a significantly improved engraftment of slow off-rate T cell 203 
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clones compared with fast off-rate T cell clones (Figure 4F). Yet, tumor-specific T cells did 204 
not persist beyond 14 days after T cell transfer (data not shown), in line with a previous 205 
report (35). In summary, these data provide further evidence that the TCR-pMHC off-rate 206 
represents an excellent biomarker to predict the immunotherapeutic potential of tumor-207 
specific CD8 T cells, and could therefore be selectively used to enhance the efficacy of 208 
adoptive T cell therapy (27). 209 
 210 
TCR-pMHC off-rates vary according to the antigenic specificity of CD8 T cells 211 
Only limited information is available on the overall quality of TCR-pMHC binding avidity of 212 
self/tumor- versus non-self/pathogen-specific CD8 T cell repertoires (36, 37). To address this 213 
point, we performed a comprehensive analysis of TCR-pMHC off-rates on 414 effector-214 
memory CD8 T cell clones specific for (i) the differentiation antigen A2/Melan-A26-35, (ii) 215 
the cancer testis antigen A2/NY-ESO-1157-165, (iii) the viral CMV/pp65495-504 antigen and (iv) 216 
the viral EBV/BMFL1259-267 antigen isolated from five melanoma patients and two healthy 217 
donors (Figure 5, A and B; Supplemental Figure 6, A and B). TCR-pMHC off-rate 218 
repertoires varied according to the T cell antigenic specificity. As such, A2/Melan-A26-35 -219 
specific CD8 T cells displayed significantly faster TCR-pMHC off-rates than the A2/NY-220 
ESO-1157-165-specific ones. Moreover, both tumor-specific TCR repertoires exhibited 221 
significantly faster TCR-pMHC off-rates than repertoires specific for herpes virus antigens 222 
(A2/pp65495-504 and A2/BMFL1259-267). Due to the presence of highly frequent TCR 223 
clonotypes potentially biasing the NY-ESO-1- and CMV-specific and to a lesser extent the 224 
EBV- and Melan-A-specific CD8 T cell repertoires (38-40), we performed an extensive 225 
TCR-BV-CDR3 clonotyping of 353 effector-memory CD8 T cell clones (Figure 5C; 226 
Supplemental Table 1). We identified 143 individual clonotypes (specific for A2/MelanA- 227 
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and A2/NYESO1-tumor antigens, and A2/pp65- and A2/BMLF1-viral epitopes), representing 228 
about 40% of the clonotype diversity, and depending on the antigenic specificity (Melan-A26–229 
35 > EBV/BMFL1259-267 > NY-ESO-1157-165 and CMV/pp65495-504). The same TCR-pMHC 230 
off-rate hierarchy (virus-specific > self/tumor-specific CD8 T cells) was observed when 231 
considering all CD8 T cell clones (Figure 5B) or only the individual TCR clonotypes 232 
(Figure 5C). Finally, similar differences were obtained when the CD8 T cell clones were 233 
subdivided according to their ex vivo differentiation status (early-differentiated EM/CD28+ 234 
or late-differentiated EM/EMRA/CD28-; Supplemental Figure 6C).  235 
The differences found between A2/Melan-A26-35- and A2/NY-ESO-1157-165-specific 236 
repertoires may result from the fact that the A2/Melan-A26-35-specific clones were derived 237 
following peptide vaccination combined to CpG and IFA adjuvant (41), when compared to 238 
the NY-ESO-1 repertoire obtained from patients with naturally-occurring T cell responses. 239 
Thus, we investigated the quality of the natural A2/MelanA26-35-specific CD8 T cell 240 
repertoires found in unvaccinated melanoma patients (n = 2), as well as in A2-positive and 241 
A2-negative individuals without melanoma (n = 4), known to express an unusually large 242 
peripheral repertoire of naïve (CD45RA+CCR7+) A2/MelanA26-35-reactive CD8 T cells (42). 243 
Unvaccinated patients exhibited differentiated A2/Melan-A26-35-specific T cell repertoires of 244 
significantly faster off-rates when compared to the ones derived from vaccinated melanoma 245 
patients (Figure 5D). Strikingly, similar rapid off-rates were observed for the 246 
CD45RA+CCR7+ naïve-specific T cell repertoires derived from unvaccinated patients as well 247 
as from A2-positive and A2-negative healthy individuals. These observations reveal the 248 
overall inferior quality of the TCR-pMHC binding repertoires specific for the self-A2/Melan-249 
A26-35 epitope, when compared to the ones specific for the cancer testis A2/NY-ESO-1 or 250 
viral antigens. Yet, several clones of slower off-rates could still be detected, indicating the 251 
presence of rare self/Melan-A-specific T cells of high binding avidity within the endogenous 252 
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unvaccinated repertoire. Finally, our data show that higher avidity T cells can be selected 253 
following therapeutic vaccination, emphasizing the relevance of therapeutic vaccination 254 
approaches in enhancing the quality of a tumor-specific repertoire. 255 
 256 
TCR-pMHC off-rate is a stable and robust biomarker independent of the activation 257 
state of the T cell 258 
CD8 T cell functional avidity represents a biological readout that is potentially influenced by 259 
multiple factors, such as TCR-pMHC binding avidity, TCR and CD8 surface expression as 260 
well as various molecules regulating TCR signaling and T cell function (10). In that regard, 261 
the TCR-pMHC off-rate may provide a more reliable biophysical parameter than the widely 262 
used functional-related methods to assess T cell potency. To investigate this question, we first 263 
compared the variations obtained following separate experimental measurements (n = 4 to 9) 264 
of TCR-based dissociation rates, multimer staining intensity levels and EC50 killing avidity 265 
of twelve representative Melan-A-specific CD8 T cell clones. For each individual clone, the 266 
inter-experimental off-rate values nicely clustered together, in sharp contrast to the repeat 267 
multimer staining and functional avidity experiments showing large disparities (Figure 6, A-268 
C). Furthermore, the average dissociation rates of these clones strongly correlated with 269 
average EC50 killing avidity, but not with average multimer staining intensity (Supplemental 270 
Figure 7A). Finally, no correlation was found between functional avidity and multimer 271 
staining levels, in agreement with previous reports (reviewed in (26)). We next performed 272 
longitudinal measurements of TCR-pMHC off-rates and EC50 killing avidity on a 273 
representative panel of A2/Melan-A26-35-specific CD8 T cell clones following non-specific in 274 
vitro stimulation with PHA and feeder cells (Supplemental Figure 7, B and C). We 275 
observed a remarkable stability of TCR-pMHC off-rate measurements upon stimulation, even 276 
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when tested at a 6-month interval on T cell clones that underwent several additional rounds of 277 
PHA/feeder expansion (Figure 6D). In contrast and as previously described (43), for a given 278 
T cell clone, the killing avidity greatly varied and augmented up to 10-fold, according to the 279 
time elapsed since the last stimulation (Figure 6E). These data indicate that the functional 280 
avidity reflects the in vitro activation status of CD8 T cells, in line with the up-regulation of 281 
cell-surface expression of TCRαβ, CD8αβ, and VLA-1 integrin and, conversely the down-282 
regulation of VLA-4 integrin and several co-inhibitory receptors such as CD5, LAG-3 and 283 
TIGIT or the co-stimulatory receptor CD28 (Figure 6F). Importantly, the TCR-pMHC 284 
binding off-rate measurement is independent of TCRαβ levels, and stands out as a more 285 
stable and reliable biomarker than the usually performed assessments of multimer staining 286 
levels (i.e. mean fluorescence intensity) or EC50 functional avidity.   287 
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DISCUSSION 288 
Several observations support the importance of considering both quantitative (i.e. magnitude 289 
of response) and qualitative (i.e. functional avidity, polyfunctionality) determinants of the T 290 
cell response, in order to predict in vivo efficacy (reviewed in (10)). However, ex vivo 291 
functional avidity or EC50 (using titrated functional assays) and polyfunctionality assessments 292 
still remain laborious and time consuming, and often not possible because relatively large cell 293 
numbers must be withdrawn from patients. Importantly, and as shown in the current study, 294 
EC50 values largely depend on the T cell’s activation state, and are thus influenced by intra-295 
experimental (i.e. over time experimental measurements following T cell stimulation) and 296 
inter-experimental (i.e. separate experimental measurements) variability/fluctuations (Figure 297 
6). Moreover, functional avidity varies greatly depending on the functional readouts (e.g. 298 
cytotoxicity versus cytokine production), which mostly reflects modulation of the function-299 
specific activation thresholds (cytotoxicity < cytokine production) (Figure 1, Supplemental 300 
Fig. 4A). Taken together, there is a strong need to identify a T cell-based biomarker that 301 
overcomes the major limitations associated to functional assays and provides a reliable, 302 
simple to use, amenable to standardization immune metric for immunotherapy of cancer or 303 
chronic microbial infections. 304 
Here, using an extensive and representative panel of antigen-specific CD8 T cells generated 305 
in the context of natural or post-vaccination immune responses, we show that the TCR-ligand 306 
dissociation rate globally correlated to all aspects of CD8 T cell functions tested (i.e. 307 
cytotoxic activity, CD107a degranulation, cytokine production, proliferation and co-receptor 308 
modulation; Figure 1 and 3), including polyfunctionality (Figure 2) of both self/tumor- and 309 
virus-specific CD8 T cells. Nonetheless, virus-specific T cells displayed weaker, although 310 
statistically significant correlations, than tumor-specific T cells, which may in part be the 311 
consequence of their overall slower TCR off-rates. These data nicely fit with the model 312 
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proposing that enhanced TCR affinity or off-rate correlates with improved T cell 313 
responsiveness, but that this correlation is no longer linear above a certain TCR binding 314 
avidity threshold (reviewed in (26)). Specifically, using artificial affinity-enhanced TCRs, 315 
several reports (30, 44, 45) have shown that maximal T cell responsiveness occurs within an 316 
optimal window of TCR-pMHC binding interactions, usually lying in the upper physiological 317 
affinity range (KD between 10 to 1 µM), and encompassing naturally occurring non-318 
self/virus-specific TCR repertoires (36, 37). Moreover, the monomeric TCR-pMHC off-rate 319 
also predicted the relative tumor control activity in vivo (Figure 4). Importantly, as a 320 
biophysical readout, the TCR-pMHC off-rate represents a more stable and robust parameter 321 
of T cell potency, compared to the fluctuating biological metrics, such as T cell functional 322 
avidity or multimer-staining levels, which instead depend on the activation status of the cell 323 
(Figure 6). Our observations are in agreement with other studies showing that functional 324 
avidity is not a constant parameter in individual T cell clones, but gradually increases with 325 
time after in vitro restimulation (43, 46) or during the early course of acute viral infection in 326 
vivo (47). Enhanced antigen sensitivity is notably influenced by the differential expression of 327 
TCRαβ and accessory molecules (i.e. increased CD8αβ and VLA-1 versus reduced CD28, 328 
LAG-3 and TIGIT expression) (Figure 6). Altogether, the TCR-pMHC off-rate stands out as 329 
a major and stable determinant of CD8 T cell function, allowing to accurately monitor the 330 
quality of naturally occurring or vaccinated-induced self/tumor-specific T cell responses, but 331 
also to identify the most potent CD8 T cells for adoptive transfer therapy.  332 
Up-to-date, a debate remains regarding which parameter(s) of the TCR-pMHC interactions 333 
(e.g. KD, koff, kon) could better predict T cell activation and subsequent response potency. 334 
Several studies reported that the dissociation rate (koff) was the most significant factor (27, 335 
45), whereas others proposed that the dissociation constant KD was the preeminent correlate 336 
of T cell responsiveness (44, 48). However, the association rate parameter, kon, may also 337 
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contribute to the response potency (49, 50). In that regard, Aleksic et al. (51) and Govern et 338 
al. (52) proposed that these apparently contradictory observations might in fact reflect the 339 
impact of fast versus slow association rates on the TCR-pMHC binding duration. Indeed, at 340 
the cell interface, fast kon rates would allow rapid rebinding of the same TCR-ligand complex 341 
after dissociation, resulting in enhanced effective dissociation half-lives. Molecular TCR-342 
pMHC binding interactions are usually assessed by SPR measurements in solution (3D 343 
binding), which fail to take into account the kon-associated rapid rebinding effect of the TCR 344 
to the same pMHC. The NTAmer-based approach deviates in that regard from SPR 345 
measurements. Using a panel of CD8 T cells engineered to express TCR variants of 346 
increasing affinities for pMHC, we previously observed that TCRs with fast kon had 347 
prolonged NTAmer-based dissociation half-lives compared to those with slow kon (28). Thus, 348 
NTAmers may somehow reflect additional membrane-associated kinetic aspects (i.e. impact 349 
of rebinding and CD8 coreceptor), which are typically integrated by the 2D surface-based 350 
kinetic analyses (reviewed in (53)). Despite its current limitations (T cell cloning 351 
requirement, no direct kon readouts), the NTAmer technology allows for rapid and accurate 352 
real-time off-rate measurements of large panels of naturally-occurring antigen-specific CD8 353 
T cells, that may display a broad range of TCR-pMHC affinities, including weak interactions 354 
((28, 29), current manuscript). Finally, a tight correlation between TCR off-rates and T cell 355 
antigenic sensitivity was not always observed, and notably depended on the antigenic 356 
specificity of the cells, but also on the T cell functional readout (Figure 1 and 3). However, 357 
robust statistical evaluation did not identify consistent outlier clones (i.e. the same clone that 358 
behaved as an outlier in one functional assay was not an outlier in the other functional 359 
assays). Thus, the few outlier data that we observed might best be explained by the 360 
variability/fluctuations related to biological measures (Figure 6), yet we cannot entirely 361 
exclude an impact of the kon parameter, possibly influencing T cell responsiveness (49, 50). 362 
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In depth kon evaluation of such exceptions would be highly useful, however only feasible 363 
once novel technologies that can interrogate all TCR-pMHC binding parameters directly on 364 
living T cells will become available.  365 
Extending on previous studies showing a positive correlation between PD-1 expression and 366 
TCR-pMHC avidity (30) or functional avidity (31), NTAmer-based off-rates nicely predicted 367 
the up-modulation of both co-stimulatory (CD28, 4-1BB) and co-inhibitory (PD-1, LAG-3, 368 
TIM-3, TIGIT) receptors upon antigen-specific stimulation (Figure 3). Thus, our results 369 
indicate that T cells of higher binding avidity are more susceptible to activation and 370 
subsequent upregulation of activating/inhibitory receptors than lower avidity ones. 371 
Expression of inhibitory receptors such as PD-1 is usually considered as a hallmark of T cell 372 
exhaustion in chronic infection and cancer, and consequently high avidity T cells may be 373 
more prone to functional impairment. However, Odorizzi et al. (54) recently found that 374 
genetic absence of PD-1 on CD8 T cells does not prevent exhaustion during chronic LCMV 375 
infection. Instead, PD-1 also plays a critical role in protecting T cells from overstimulation, 376 
excessive proliferation and terminal differentiation (54) and identifies highly reactive anti-377 
tumor T lymphocytes (55). Moreover, T cell differentiation and activation are major drivers 378 
of inhibitory receptor expression (56). Together, the extent of co-receptor up-modulation 379 
observed following stimulation (Figure 3) likely reveals the overall antigen sensitivity of the 380 
T cells, which is mostly driven by TCR-pMHC binding avidity.  381 
Another major finding is that the TCR-pMHC dissociation rate parameter allows the direct 382 
comparison across various antigen-specific T cell repertoires, in contrast to functional assays. 383 
The latter ones rely on the stability of the pMHC complexes, which is not the case for 384 
monomeric TCR-pMHC dissociation experiments. Indeed, the stability of peptide binding to 385 
MHC may highly vary between different antigens even when presented by the same HLA-386 
A*0201 molecule. This may help explaining why direct comparisons of in vitro functional 387 
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avidities (i.e. EC50) between tumor- and virus-specific T cell clones, or between Melan-A26-35 388 
and NY-ESO-1157-165 or CMV/pp65495-504 and EBV/BMFL1259-267 specificities show such 389 
divergent differences (Figure 1, Supplemental Fig. 4B). For instance, Melan-A- and EBV-390 
specific T cell clones generally exhibit the lowest EC50 functional avidities, whereas NY-391 
ESO-1- and CMV-specific T cell clones share the highest ones. In contrast, this is no longer 392 
an issue for the off-rate measurements, which rely by definition on the dissociation rate 393 
between the TCR and a given pMHC complex at the monomeric level. Consequently, we 394 
were able to directly compare large T cell clonotype repertoires (n > 300) across four 395 
different antigenic specificities and confirm strong binding differences between self/tumor 396 
and virus-specific CD8 T cells (Figure 5; (36, 37)). Specifically, virus-specific CD8 T cell 397 
repertoires were endowed with longer TCR-pMHC dissociation-rates than self/tumor-specific 398 
one. These data nicely support the concept that many tumor antigens are in fact self-antigens, 399 
and consequently mechanisms of central and peripheral tolerance shape the self/antigen-400 
specific repertoires towards lower TCR avidities by removing high-avidity self-reactive T 401 
cells (23, 57).  402 
Fluorochrome-conjugated pMHC reagents are widely used for the detection and analysis of 403 
antigen-specific CD8 T cells. Various reports have previously shown that certain functional 404 
antigen-specific CD8 T cells fail to bind tetrameric MHC ligands, which could represent up 405 
to several percent of the CD8 T cell subset (58-60). Moreover, this is of particular importance 406 
when staining tumor-specific CD8 T cells, known to express lower TCR-pMHC 407 
affinity/avidity repertoires than virus-specific cells (Figure 5; (36, 37)). We therefore used 408 
pMHC multimer and NTAmer molecules to detect tumor-specific CD8 T cells, which 409 
consistently displayed higher sensitivity than Streptamers or Pentamers (Supplemental Fig. 410 
1A) or pMHC tetramer molecules (data not shown). However, we cannot entirely exclude 411 
that a sizeable fraction of antigen-specific T cells may not be stained by these higher 412 
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sensitivity tools and may therefore be ignored in our experimental setting.  413 
The Melan-A/MART-1 26-35 antigenic peptide is among the best-studied human tumor-414 
associated antigens. We have previously documented that the frequency of naive A2/Melan-415 
A26-35-specific CD8 T cells is unusually high, because of the large numbers selected in the 416 
thymus (42). A recent study reported that medullary thymic epithelial cells express a 417 
truncated Melan-A transcript, which precludes clonal deletion (central tolerance) to this 418 
antigen due to the lack of the expression of the immunodominant 26-35 epitope (61). Another 419 
interesting explanation might lay in the impact of certain germ line TCR gene segments, 420 
notably the TRAV12-2 gene dominant in the Melan-A antigen specific T cell repertoire, on 421 
contributing substantial binding affinity for the HLA-A2/Melan-A 26-35 complex (62). One 422 
additional plausible cause of the presence of this large Melan-A26-35-reactive T cell repertoire 423 
is that it could be positively selected through the recognition of unknown Melan-A cross-424 
reactive peptides expressed in the thymus (63, 64). Here, we found that naive Melan-A26-35-425 
reactive repertoires isolated from either healthy individuals or unvaccinated melanoma 426 
patients depicted an overall poor TCR binding avidity, when compared to the primed 427 
repertoires from vaccinated patients (Figure 5). Thus, our observation are compatible with 428 
central tolerance mechanisms, possibly involving other cross-reactive self-antigens, and 429 
restricting the Melan-A26-35-reactive T cell repertoire to the lower avidity range. Yet, 430 
although rare, our large-scale study could identify few self/ Melan-A26-35-specific naive CD8 431 
T cells of higher binding avidities within healthy individual’s and patient’s repertoires, 432 
extending and refining prior studies performed using conventional pMHC class-I fluorescent 433 
multimers (65). Therefore, it is possible that therapeutic vaccination allows for the selection 434 
and expansion of a wide Melan-A-reactive TCR avidity repertoire, which includes highly-435 
specific T cells sharing similar binding avidities than those present in the cancer testis 436 
A2/NY-ESO-1-specific repertoire.  437 
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Finally, our results highlight the importance of optimizing the choice of tumor antigens for 438 
the development of cancer-based immunotherapies. Notably, it remains to be determined 439 
whether T cell repertoires targeting tumor-derived neoantigens can display greater TCR-440 
pMHC binding avidities than self/tumor-antigen ones, since neoantigen-specific T cells are 441 
more likely to escape thymic negative selection (66). It is tempting to speculate that potent 442 
neoantigen-specific CD8 T cells would display TCR off-rates of magnitude closer to the 443 
kinetics of viral-specific CD8 T cells shown in this study. 444 
Large-scale ex vivo assessment of TCR-pMHC binding kinetics was until recently 445 
technically challenging, underestimating the overall impact and clinical relevance of this 446 
biophysical parameter in the context of antigen-specific CD8 T cell repertoires. Based on 447 
monomeric TCR-pMHC off-rate measurements (i.e. NTAmers), we here demonstrated that 448 
the koff parameter represents a powerful biomarker to characterize in vitro and in vivo CD8 T 449 
cell potency within antigen-specific CD8 T cell responses. Yet, robust techniques allowing 450 
for the rapid identification and isolation of CD8 T cells of highest avidity and functions 451 
directly ex vivo from tissues or blood samples and at the single cell level are still required. In 452 
that regard, Nauerth and colleagues (67) proposed that small polyclonal virus-specific CD8 T 453 
cell populations could be analyzed directly ex vivo without the need of previous TCR cloning 454 
or T cell sorting. The recent implementation of an ex vivo platform allowing for the single 455 
cell serial determination of 2D TCR-pMHC affinity (based on micropipette adhesion 456 
frequency) and TCR-clonotyping is also highly promising (68). In conclusion, recent 457 
technological breakthroughs now enable the rapid development of TCR-pMHC binding 458 
kinetics-based simple assays as sensitive and reliable biomarkers of CD8 T cell activity and 459 
clinical efficacy.  460 
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METHODS 461 
Patients, healthy donors and ethics statement 462 
Peripheral blood samples were collected from HLA-A*0201-negative (HD1 & HD2), HLA-463 
A*0201-positive (HD3 & HD4), HLA-A*0201- positive and CMV/EBV-chronically infected 464 
(BCL4 & BCL6) healthy donors (HD) (39) and from HLA-A*0201-positive stage III/IV 465 
metastatic melanoma patients included in immunotherapy studies (patient LAU50; 466 
NCT00112242, patient LAU155; NCT00002669, and patients LAU975, LAU1013, LAU618, 467 
LAU627 and LAU818; NCT00112229; www.clinicaltrials.gov) (38, 41, 69). Patients 468 
LAU618, LAU627 and LAU818 received 8 to 12 monthly low-dose vaccinations injected s.c. 469 
with 100 μg high-affinity Melan-A26-35 (A27L) analog peptide mixed with 0.5 mg CpG 470 
7909/PF-3512676 (Pfizer and Coley Pharmaceutical Group) and emulsified in IFA 471 
(Montanide ISA-51, Seppic). Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) centrifuged 472 
peripheral blood mononuclear cells (PBMCs) were cryopreserved in 10% DMSO and stored 473 
in liquid nitrogen until further use. 474 
Generation of antigen-specific CD8 T cell clones 475 
Thawed PBMCs were positively enriched using anti-CD8-coated magnetic microbeads 476 
(Miltenyi Biotec), stained in PBS, 0.2% BSA and 5 mM EDTA with PE-labeled HLA-477 
A*0201 multimers (loaded with analog Melan-A26–35(A27L), NY-ESO-1157-165(C165A), and 478 
EBV/BMFL1259-267(C260A), or native CMV/pp65495-504 peptide) (TCMetrix Sàrl) at 4oC for 45 479 
min, followed by cell surface markers (APC anti-CD28, FITC anti-CD45RA (BD 480 
Pharmingen), PE-Cy7 anti-CCR7 (BioLegend), APC-A750 anti-CD8 (Beckman Coulter), 481 
Supplemental Table 2) at 4oC for 30 min. Cells were then sorted into defined differentiated 482 
subpopulations (naïve, CD45RA+CCR7+CD28+; effector-memory (EM) CD45RA-CCR7-483 
CD28+/- or EMRA, CD45RA+CCR7-CD28-) of antigen-specific CD8 T cells on a FACSAria 484 
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(BD Biosciences) or Astrios (Beckman Coulter) flow cytometer. Sorted cells were cloned by 485 
limiting dilution in Terasaki plates and expanded in RPMI 1640 medium supplemented with 486 
8% human serum, 150 U/ml human rIL-2 (gift of GlaxoSmithKline), 1 μg/ml PHA (Sodiag) 487 
and 1x106/ml 30-Gy irradiated allogeneic PBMCs. The antigenic specificity of CD8 T cell 488 
clones was controlled by HLA-A*0201/peptide multimer stainings (TCMetrix Sàrl). 489 
Extensive TCR-BV-CDR3 clonotyping was performed on the T cells from patients LAU618, 490 
LAU155 and LAU50 and from healthy donors BCL4 & BCL6, as previously described (39), 491 
allowing selecting representative sets of dominant (with frequency >5%) and non-dominant 492 
TCR-BV-CDR3 clonotypes. Clonotype diversity varied from 43% to 80%, depending on the 493 
antigenic specificity (Melan-A26–35 > EBV/BMFL1259-267 > NY-ESO-1157-165 and 494 
CMV/pp65495-504) and is indicated throughout the manuscript.  495 
NTAmer staining and dissociation kinetic measurements 496 
The pMHC multimer and NTAmer molecules used in this study carry 8 to 12 pMHC 497 
monomers per conjugate, similarly to Dextramer molecules. Importantly, multimers and 498 
NTAmers provided a superior ex vivo detection of A2/MelanA-specific CD8 T cells from 499 
PBMCs of two melanoma patients, when compared to Pentamers (5 pMHC monomers) or 500 
Streptamers (5-7 pMHC monomers) (Supplemental Figure 1A). NTAmers are dually 501 
labeled pMHC multimers built on NTA-Ni2+-His-tag interactions (70) and were used for 502 
dissociation kinetic measurements as described previously (28, 29). Briefly, individual 503 
antigen-specific CD8 T cell clones were stained for 45 min at 4°C in PBS, 0.2% BSA and 5 504 
mM EDTA with antigen-specific NTAmers, in which the HLA-A*0201 molecules were 505 
loaded with the native Melan-A26–35, NY-ESO-1157-165, EBV/BMFL1259-267, or CMV/pp65495-506 
504 peptide. Of note, Melan-A- and NY-ESO-1-specific T cells isolated from melanoma 507 
patients as well as EBV-specific T cells from healthy donor BCL4 were initially sorted with 508 
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the analog-peptide multimers. Yet, all Melan-A-, NY-ESO1- and EBV-derived T cell clones 509 
presented a high degree of cross-reactivity, since native-peptide NTAmers showed a 510 
comparable capacity to stably label each generated specific clone and thus should not have 511 
introduced a significant bias in the analysis. NTAmer staining was assessed at 4°C on a 512 
SORP-LSR II flow cytometer (BD Biosciences). Following 1 min of baseline acquisition, 513 
imidazole (100 mM) was added and Cy5 fluorescence measured during the following 10 min. 514 
Data were analyzed using the kinetic module of the FlowJo software (v.9.7.6, Tree Star) and 515 
modeled (one phase exponential decay) using the Prism software (v.6, GraphPad). 516 
Chromium release cytolytic assay 517 
Chromium release cytolytic assays were performed as previously described (13). Briefly, 518 
51Cr-labeled HLA-A*0201-positive TAP-deficient T2 cells were pulsed with serial dilutions 519 
of native Melan-A26–35, NY-ESO-1157-165, EBV/BMFL1259-267, or CMV/pp65495-504 peptides, 520 
and incubated with antigen-specific CD8 T cell clones at an E:T ratio of 10:1 for 4h. NY-521 
ESO-1157-165 and EBV BMFL1259-267 peptides were pre-incubated for 1h at room temperature 522 
with 2 mM of disulfide-reducing agent Tris [2-carboxyethyl] phosphine (TCEP, Pierce 523 
Biotechnology). Percentages of specific lysis were calculated as 100 x (experimental - 524 
spontaneous release)/(total - spontaneous release). EC50 and Bmax values were derived by 525 
dose-response curve analysis (log(agonist) versus response) using the Prism software (v.6, 526 
GraphPad). Non-killer clones were defined as displaying a maximal lysis <25% and/or for 527 
which an EC50 value could not be accurately determined. These non-killer clones were 528 
excluded from the statistical analyses. 529 
CD107a degranulation & intracellular cytokine staining   530 
HLA-A*0201-positive TAP-deficient T2 cells were pulsed 1h at 37°C with serial dilutions of 531 
the native Melan-A26–35, NY-ESO-1157-165, EBV/BMFL1259-267, or CMV/pp65495-504 peptides, 532 
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washed and incubated with antigen-specific CD8 T cell clones at an E:T ratio of 1:2 for 6h in 533 
the presence of FITC anti-CD107a (BD Pharmingen; Supplemental Table 2) and Brefeldin 534 
A (10μg/ml, Sigma). NY-ESO-1157-165 and EBV BMFL1259-267 peptide were pre-incubated for 535 
1h at room temperature with the disulfide-reducing agent TCEP (2 mM; Pierce 536 
Biotechnology). Cells were then stained in PBS, 0.2% BSA, 5 mM EDTA and 0.2% NaN3 537 
with Pacific-Blue anti-CD8α (Beckman Coulter) at 4°C for 30 min, fixed in PBS 1% 538 
formaldehyde, 2% glucose and 5 mM NaN3 for 20 min at RT, and finally stained in PBS, 539 
0.2% BSA, 5 mM EDTA, 0.2% NaN3 and 0.1% Saponin (Sigma) with PerCPCy5.5 anti-IL-540 
2, APC anti-IL-13, PE-Cy7 anti-IFNγ, A700 anti-TNFα (BD Pharmingen; Supplemental 541 
Table 2) and PE anti-IL-4 (Biolegend) for 30 min at 4°C before acquisition on a Gallios 542 
(Beckman Coulter) flow cytometer. Percentages of CD107a/cytokine-positive T cells were 543 
analyzed using the FlowJo software (v.10.0.7, Tree Star). EC50 and Bmax values were derived 544 
by dose-response curve analysis (log(agonist) versus response) using the Prism software (v.6, 545 
GraphPad). Non-cytokine clones were defined as displaying a maximal response <25% and 546 
for which an EC50 value could not be determined accurately. These non-cytokine clones were 547 
not included in the statistical analyses. CD107a, IL-2, IFNγ and TNFαco-expression were 548 
analyzed using the SPICE software (v.5.35, National Institute of Allergy & Infectious 549 
Diseases). 550 
Proliferation assay 551 
30-Gy irradiated HLA-A*0201-positive PBMCs were pulsed 1h at 37°C with native Melan-552 
A26–35 (10 μM), NY-ESO-1157-165 (1 μM), EBV/BMFL1259-267 (1 μM), or CMV/pp65495-504 553 
peptides (0.01 μM), washed and incubated with CellTraceViolet-stained antigen-specific 554 
CD8 T cell clones (ThermoFischer) at an E:T ratio of 1:2 in RPMI 1640 medium 555 
supplemented with 8% human serum and 50 U/ml human rIL-2 (gift of GlaxoSmithKline). 556 
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NY-ESO-1157-165 and EBV/BMFL1259-267 peptides were pre-incubated for 1h at room 557 
temperature with the disulfide-reducing agent TCEP (2 mM, Pierce Biotechnology). After 7 558 
days, antigen-specific CD8 T cell clones were acquired on a Gallios (Beckman Coulter) flow 559 
cytometer. Percentages of divided cells were analyzed using the proliferation module of the 560 
FlowJo software (v.9.7.6, Tree Star). 561 
Surface marker expression/modulation assay 562 
For co-receptor modulation assays, antigen-specific CD8 T cell clones were incubated for 563 
24h in the absence or presence of HLA-A*0201 unlabeled tetramers loaded with native 564 
Melan-A26–35 (1 μg/ml), NY-ESO-1157-165 (1 μg/ml), EBV BMFL1259-267 (0.1 μg/ml), or CMV 565 
pp65495-504 (0.01 μg/ml) peptides. Cells were then stained in PBS, 0.2% BSA, 5 mM EDTA 566 
and 0.2% NaAzide with (i) A488 anti-PD1 (Serotec), PE-Cy7 anti-CD5 (BD Pharmingen), 567 
APC anti-TIGIT (eBioscience) and BrV421 anti-CD28 (Biolegend), or with (ii) FITC anti-568 
LAG-3 (Enzo), PE anti-TIM-3 (R&D Systems) and APC anti-CD137 (BD Pharmingen) at 569 
4°C for 30 min and acquired on a Gallios (Beckman Coulter) flow cytometer. Markers 570 
expression (gMFI) was analyzed using the FlowJo software (v.10.0.7, Tree Star) and their 571 
modulation was calculated as (gMFI of stimulated cells) / (gMFI of un-stimulated cells).  572 
For over time expression assays, tumor-specific CD8 T cell clones were stimulated and 573 
expanded upon PHA and irradiated feeder cells, and stained overtime (at day 10, 15 and 20) 574 
in PBS, 0.2% BSA, 5 mM EDTA and 0.2% NaAzide with FITC anti-CD8β, PE-Cy7 anti-575 
CD8α, PE anti-pan-TCRαβ (Beckman Coulter), PE anti-VLA-1, PE-Cy7 anti-CD5, APC 576 
anti-VLA-4, APC anti-CD137, BrV421 anti-PD1 (BD Pharmingen), APC anti-TIGIT 577 
(eBioscience), BrV421 anti-CD28 (Biolegend) or FITC anti-LAG-3 (Enzo) at 4°C for 30 578 
min, and acquired, using identical settings, on a Gallios (Beckman Coulter) flow cytometer. 579 
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Supplemental Table 2 contains a detailed list and information of all antibodies used in this 580 
study.  581 
Adoptive T cell transfer in immunodeficient mice 582 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (Jackson, stock number 005557) were bred in 583 
the conventional animal facility of the University of Lausanne under SPF status. Six to nine 584 
weeks old female mice were anesthetized with isofluran and subcutaneously injected with 585 
1x106 A2/Melan-A26–35- and A2/NY-ESO-1157-165-positive human melanoma Me275 tumor 586 
cells (grown in DMEM medium supplemented with 10% FCS, and previously passed in NSG 587 
mice for A2/NY-ESO-1157-165-specific experiments). Once the tumors became palpable 588 
(around D14 to 20), 1x106 human tumor-specific CD8 T cell clones were injected 589 
intravenously in the tail vein. For A2/NY-ESO-1157-165-specific experiments, 1x106 T cell 590 
clones were administrated twice at D14 and D21, followed by 3 daily subcutaneously 591 
injections of human rIL-2 (3x104 U; gift of GlaxoSmithKline), starting at the day of T cell 592 
transfer. Tumor volumes were measured by caliper twice a week and calculated as follow: 593 
volume = length x width x width/2. Mice were sacrificed by CO2 inhalation before the tumor 594 
volume exceeded 1000 mm3 or when necrotic skin lesions were observed at the tumor site. In 595 
separate experiments, we collected blood from tail veins at D2 and D14 after infusion of 596 
4x106 A2/NY-ESO-1157-165-specific T cell clones and analyzed the frequency of persisting 597 
human CD8 T cells by flow cytometry. This study was approved by the Veterinary Authority 598 
of the Canton de Vaud (Permit n°VD1850.5) and performed in accordance with Swiss ethical 599 
guidelines.  600 
Statistical analysis 601 
Data were analyzed using the Prism software (v.7, GraphPad) by non-parametric Spearman 602 
correlation, non-linear regression (95% confidence intervals and 10% ROUT coefficient Q 603 
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(71)), extra sum-of-squares F, Kruskal-Wallis, Mann-Whitney, Friedman, Wilcoxon-paired, 604 
two-way ANOVA and log-rank tests. The associated p values (two-tailed and α = 0.05 when 605 
applicable), as well as numbers of experiments and sample sizes are indicated throughout the 606 
manuscript.  607 
Study approvals 608 
Study protocols were designed, approved and conducted according to the relevant regulatory 609 
standards from (i) the ethical commission of the University of Lausanne (Lausanne, 610 
Switzerland), (ii) the Protocol Review Committee of the Ludwig Institute for Cancer 611 
Research (New-York) and (iii) Swissmedic (Bern, Switzerland). Healthy donors and patient 612 
recruitment, study procedures and blood withdrawal were done upon written informed 613 
consent.   614 
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FIGURE LEGENDS 865 
Figure 1:  Relationship between TCR dissociation rates and functional avidity of 866 
self/tumor- and virus-specific CD8 T cell clones. Correlations between EC50 values from 867 
(A) killing, (B) CD107a degranulation, (C) IFNγ-, (D) TNFα- and (E) IL-2-production 868 
titration assays and NTAmer-derived TCR dissociation rates (koff). (F) Correlations between 869 
percentages of proliferating cells upon antigen-specific stimulation and NTAmer-derived 870 
TCR dissociation rates (koff). (A-F) Antigen-specific CD8 T cell clones were generated upon 871 
direct ex vivo sorting from effector-memory (EM)/CD28+/- and/or EMRA/CD28- subsets. 872 
Each data point represents an A2/Melan-A26-35- (derived from patient LAU618, ), A2/NY-873 
ESO-1157-165- (patient LAU155, ), A2/pp65495-504- or A2/BMFL1259-267- (healthy donor 874 
BCL4, ) specific individual T cell clone. Non-functional clones are represented in grey 875 
boxes. The number of clones displaying function n, as well as Spearman’s correlation (two 876 
tailed, α = 0.05) coefficients R and p values are indicated. Color-coded and black lines are 877 
indicative of regression fitting and 95% confidence intervals, respectively. Of note, only very 878 
low numbers of outliers were identified when applying the ROUT method and are 879 
highlighted in color (71). The representative TCR-BV-CDR3 clonotype diversity of each 880 
antigenic specificity was; LAU618/Melan-A, 77%; LAU155/NY-ESO-1, 43%; BCL4/pp65, 881 
57%; BCL4/BMFL1, 67%. 882 
 883 
Figure 2: Relationship between TCR dissociation rates and polyfunctionality of 884 
self/tumor- and virus-specific CD8 T cell clones. (A) CD107a, IFNγ, TNFα and IL-2 co-885 
expression titration assays of A2/Melan-A26-35- (derived from patient LAU618), A2/NY-886 
ESO-1157-165- (patient LAU155), A2/pp65495-504- or A2/BMFL1259-267- (healthy donor BCL4) 887 
specific clones with slow (n = 10) or fast (n = 10) TCR off-rates. Pie arcs depict the average 888 
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fraction of cells displaying 0 to 4 functions. (B-C) Individual and (D) average ± SEM 889 
polyfunctional (co-expression of CD107a, IFNγ, TNFα and IL-2) titration curves obtained 890 
for A2/Melan-A26-35- (derived from patient LAU618), A2/NY-ESO-1157-165-  (patient 891 
LAU155), A2/pp65495-504- or A2/BMFL1259-267- (healthy donor BCL4) specific clones with 892 
slow (n = 10, plain symbols and solid lines) or fast (n = 10, empty symbols and dotted lines) 893 
TCR off-rates Vertical lines indicated EC50 values. The p values were determined by the 894 
extra sum-of-squares F-test (α = 0.05). The representative TCR-BV-CDR3 clonotype 895 
diversity of each antigenic specificity was; LAU618/Melan-A, 80%; LAU155/NY-ESO-1, 896 
45%; BCL4/pp65, 65%; BCL4/BMFL1, 80%. 897 
 898 
Figure 3: Relationship between TCR dissociation rates and activating/inhibitory 899 
receptor expression of self/tumor- and virus-specific CD8 T cell clones. Correlations 900 
between fold increases in surface expression of (A) CD28, (B) CD137, (C) LAG-3, (D) PD-901 
1, (E) TIGIT and (F) TIM-3 upon antigen-specific stimulation and NTAmer-derived TCR 902 
dissociation rates (koff). (G) Correlations between baseline surface expression levels (gMFI) 903 
of CD5 and NTAmer-derived TCR dissociation rates (koff). (A-G) Each data point represents 904 
an A2/Melan-A26-35- (derived from patient LAU618, ), A2/NY-ESO-1157-165- (patient 905 
LAU155, ), A2/pp65495-504- or A2/BMFL1259-267- (healthy donor BCL4, ) specific 906 
individual T cell clone. The number of clones tested n, as well as Spearman’s correlation 907 
(two tailed, α = 0.05) coefficients R and p values are indicated. Color-coded and black lines 908 
are indicative of regression fitting and 95% confidence intervals, respectively. Outliers were 909 
determined by the ROUT method and are highlighted in color (71). The representative TCR-910 
BV-CDR3 clonotype diversity of each antigenic specificity was; LAU618/Melan-A, 77%; 911 
LAU155/NY-ESO-1, 43%; BCL4/pp65, 57%; BCL4/BMFL1, 67%. 912 
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 913 
Figure 4: Relationship between TCR dissociation rates and tumor control in 914 
immunodeficient mice upon adoptive T cell transfer. (A) Individual or (B) average ± SEM 915 
tumor growth and (C) Kaplan–Meier survival curves of tumor bearing NSG mice adoptively 916 
transferred with PBS (control, n = 7; black solid lines) or 1x106 A2/Melan-A26-35-specific T 917 
cell clones with fast (n = 4; blue dotted lines) or slow (n = 7; blue solid lines) TCR off-rates. 918 
(D) Individual or (E) average ± SEM tumor growth curves of tumor bearing NSG mice 919 
adoptively transferred with two-times 1x106 A2/NY-ESO-1157-165-specific T cell clones with 920 
fast (n = 5; green dotted lines) or slow (n = 5; green solid lines) TCR off-rates. Tumor 921 
volume and survival curves p values were determined by two-way-ANOVA and log-rank 922 
tests, respectively. (F) Representative staining and (G) absolute counts of human CD8 T cells 923 
from blood taken from tail veins at day 2 following adoptive transfer of 4x106 A2/NY-ESO-924 
1157-165-specific CD8 T cell clones with fast (n = 4; green empty circles) or slow (n = 3; green 925 
full circles) TCR off-rates. As control, three mice received PBS (n = 4; black squares). p 926 
values were determined by one-way ANOVA multiple comparison tests. 927 
 928 
Figure 5: TCR dissociation rates according to the antigenic specificity, clonotype 929 
repertoire and ex vivo differentiation status of CD8 T cell clones. (A, B) NTAmer-derived 930 
TCR dissociation rates (koff) of EM/EMRA CD28+/- clones (n = 414) specific for the 931 
differentiation antigen A2/Melan-A26-35 (derived from melanoma patients LAU618, LAU627 932 
and LAU818 following vaccination with Melan-A/peptide, IFA and CpG), the cancer testis 933 
A2/NY-ESO-1157-165 (from patients LAU50 and LAU155 with naturally occurring T cell 934 
responses) or the persistent herpes viruses A2/pp65495-504 or A2/BMFL1259-267 (from healthy 935 
donors BCL4 and BCL6), categorized according to (A) the respective patients and donors or 936 
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(B) antigenic specificity. (C) NTAmer-derived TCR dissociation rates (koff) of individual 937 
TCR-BV-CDR3 clonotypes specific for the tumor epitopes A2/Melan-A26-35 (n = 27) and 938 
A2/NY-ESO-1157-165 (n = 24), and the persistent herpes virus epitopes A2/pp65495-504 (n = 37) 939 
and A2/BMFL1259-267 (n = 55). (D) NTAmer-derived TCR dissociation rates (koff) of 940 
A2/Melan-A26-35-specific clones derived from HLA-A2-negative (HD1 and HD2), HLA-A2-941 
positive (HD3 and HD4) healthy donors, HLA-A2-positive unvaccinated (LAU975 and 942 
LAU1013) and A2/Melan-A26-35-vaccinated (LAU618, LAU627 and LAU818) melanoma 943 
patients, categorized according to the patient/donor groups and the differentiation status of T 944 
cell clones. (A-D) Data are depicted as box (25th to 75th percentiles) and whisker (10th to 90th 945 
percentiles) with the middle line representing the median. Numbers of clones n, as well as 946 
Kruskal-Wallis test (α = 0.05) derived p values are indicated. Significant differences between 947 
the A2/Melan-A26-35- and the A2/NY-ESO-1157-165-specific groups were obtained by Mann 948 
Whitney test (two tailed). 949 
 950 
Figure 6: Inter-experimental and over-time variations of TCR dissociation rates, pMHC 951 
multimer staining and functional avidity assays. (A) NTAmer-derived TCR dissociation 952 
rates (koff), (B) NTAmer surface staining levels (gMFI) and (C) killing avidity values (EC50) 953 
obtained in independent assays (n > 4) for A2/Melan-A26-35-specific CD8 T cell clones with 954 
slow (n = 6, plain symbols and solid lines) or fast (n = 6, empty symbols and dotted lines) 955 
TCR off-rates. (A-C) Data are depicted as individual values and box (minimum to maximum, 956 
with the middle line representing the mean). (D) NTAmer-derived TCR dissociation rates 957 
(koff), (E) killing avidity values (EC50) and (F) surface staining levels (gMFI) obtained over 958 
time (D10/11, D15 and D20/21; D = day) following non-specific stimulation (by PHA and 959 
irradiated feeder cells) for A2/Melan-A26-35-specific T cell clones with slow (n = 6, plain 960 
symbols and solid lines) or fast (n = 6, empty symbols and dotted lines) TCR off-rates. S2 961 
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represents the off-rate measurements of the same clones six months before the 5th round of 962 
stimulation (S5). The p values were determined by the Friedman (α = 0.05) and Wilcoxon 963 
matched-pair signed rank (two tailed) tests. 964 
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SUPPLEMENTAL MATERIALS  
Supplemental Table 1. List of TCR-BV-CDR3 clonotypes and their off-rate values. 
 
Supplemental Table 2. List of antibodies used in this study. 
 
  
 Supplemental Figure 1: Ex vivo detection of antigen-specific CD8 T cells using pMHC-
based reagents and analysis of blood samples used to generate self/tumor- and virus-
specific CD8 T cell clones.  (A) Comparison of A2/MelanA26-35-specific staining from 
PBMCs obtained from melanoma patients (LAU1129 and LAU1164) using PE-labeled 
pentamers, streptamers, multimers and NTAmers. Gating was done on live CD14-/CD16-
/CD19-/CD3+ lymphocytes. The valence of pMHC reagents is indicated in brackets, as well 
as percentages of positively stained cells. FMO (fluorescence minus one). (B) CD8 and 
multimer staining of CD8-enriched PBMCs from melanoma patients LAU618 (A2/Melan-
A26-35), LAU155 (A2/NY-ESO-1157-165) and healthy donor BCL4 (A2/pp65495-504 or 
A2/BMFL1259-267). (C) CCR7, CD45RA and CD28 staining of the corresponding multimer-
specific (R1) and total CD8 T cell (CD8t) populations. Percentages of positively stained cells 
are indicated. Melan-A/specific CD8 T cell clones (from patient LAU618) exhibited an 
EM/CD28+/- phenotype, while NY-ESO-1-specific T cell clones (from patient LAU155) 
presented mostly an early-differentiated EM/CD28+ phenotype. EBV/BMFL1-specific CD8 T 
cell clones were predominantly EM/CD28+, whereas CMV/pp65-specific clones mostly 
exhibited a differentiated EMRA/CD28- phenotype. 
  
 Supplemental Figure 2: In vitro analysis of TCR dissociation-rates versus functional 
avidities of self/tumor- and virus-specific CD8 T cell clones. Representative (A) NTAmer-
dissociation curves, (B) killing-, (C) CD107a degranulation-, IFNγ-, TNFα-, IL-2-, IL-4- and 
IL-13-production titration curves and (D) proliferation analysis (by CFSE fluorescence 
histograms) obtained for A2/Melan-A26-35-specific CD8 T cell clones from patient LAU618, 
defined as slow (n = 6, blue lines) or fast (n = 6, grey lines) TCR off-rates. Non-divided and 
divided T cells are represented as plain and empty peaks, respectively. 
 Supplemental Figure 3: Relationship between TCR dissociation-rates, functional avidity 
and maximal function capacity of self/tumor- and virus-specific CD8 T cell clones. 
Correlations between EC50 values from (A) IL-4- and (B) IL-13-production titration assays, 
and NTAmer-derived TCR dissociation-rates (koff). (C) Correlations between Bmax values 
from killing, CD107a-degranulation, IFNγ-, TNFα-, IL-2-, IL-4- and IL-13-production 
titration assays, or percentages of granzyme-B expressing T cells, and NTAmer-derived TCR 
dissociation-rates (koff). (A-C) Each data-point represents an A2/Melan-A26-35- (derived from 
patient LAU618, ), A2/NY-ESO-1157-165- (patient LAU155, ), A2/pp65495-504- or 
A2/BMFL1259-267- (healthy donor BCL4, ) specific individual T cell clone. Non-functional 
clones are represented in grey boxes. The number of clones displaying function n, as well as 
Spearman’s correlation (two tailed, α = 0.05) coefficient R and p values are indicated. Color-
coded and black lines are indicative of regression fitting and 95% confidence intervals, 
respectively. (D) Bmax values from killing, CD107a-degranulation, IFNγ-, TNFα-, IL-2-, IL-
4- and IL-13-production titration assays, or granzyme-B expression, of early-differentiated 
effector-memory EM/CD28+ or late-differentiated EM/CD28- A2/Melan-A26-35-specific T cell 
clones derived from patient LAU618. Data are depicted as box (25th to 75th percentiles) and 
whisker (10th to 90th percentiles) with the middle line representing the median. Numbers of 
clones n, as well as Mann-Whitney (two tailed) derived p values are indicated. Of note, upon 
high peptide-dose stimulation (at Bmax, maximal response), differentiated EM/CD28--
derived CD8 T cell clones displayed higher granzyme-B expression, cytotoxic and IFN-γ 
production capacity, but a lower ability to produce IL-2, IL-4 or IL-13 than memory 
EM/CD28+ T cells. 
 
 
 
  
 Supplemental Figure 4: Functional avidities according to the functional assay or the 
antigenic specificity of CD8 T cell clones. Comparison of functional avidity (EC50) from 
killing-, CD107a degranulation-, IFNγ-, TNFα- and IL-2-production of A2/Melan-A26-35- 
(derived from melanoma patient LAU618, n = 30), A2/NY-ESO-1157-165- (patient LAU155, n 
= 32), A2/pp65495-504- or A2/BMFL1259-267- (healthy donor BCL4, n = 30 and 26, 
respectively) specific CD8 T cell clones classified according to (A) the functional assay and 
(B) the antigenic-specificity. Data are depicted as box (minimum to maximum) with the 
middle line representing the mean. The representative TCR-BV clonotype diversity of each 
antigenic specificity is as following; LAU618/Melan-A, 77%; LAU155/NY-ESO-1, 43%; 
BCL4/pp65, 57%; BCL4/BMFL1, 67%. 
 
 
  
 Supplemental Figure 5: CD5 expression according to the TCR-dissociation off-rate 
parameter and antigenic specificity of self/tumor- and virus-specific CD8 T cell clones. 
CD5 surface staining was obtained at baseline (no antigen-specific stimulation) from 
representative antigen-specific CD8 T cells of (A) slow or (B) fast NTAmer-based off-rates. 
Data are depicted according to the antigenic specificity (A2/Melan-A26-35-, A2/NY-ESO-1157-
165-, A2/pp65495-504- and A2/BMFL1259-267 antigens). Geometric fluorescence means (gMFI) 
are indicated. 
 
  
  
Supplemental Figure 6: TCR dissociation-rates according to the antigenic specificity 
and ex vivo differentiation status. Representative (A) NTAmer-dissociation staining and (B) 
corresponding fitting curve obtained for A2/Melan-A26-35- (), A2/NY-ESO-1157-165- (), 
A2/pp65495-504- () and A2/BMFL1259-267- () specific CD8 T cell clones, defined as 
average TCR off-rates. koff and t1/2 derived values are indicated. (C) NTAmer-derived TCR 
dissociation-rates (koff) of early-differentiated effector-memory EM CD28+ (left panel) versus 
late-differentiated EM/EMRA CD28- (right panel) clones specific for (i) A2/Melan-A26-35 
(from vaccinated melanoma patients LAU618, LAU627 and LAU818), (ii) A2/NY-ESO-1157-
165 (from patients LAU50 and LAU155 with naturally occurring tumor-specific T cell 
responses) or (iii) the persistent herpes viruses A2/pp65495-504 or A2/BMFL1259-267 (from 
healthy donors BCL4 and BCL6), categorized according to their antigenic specificity. Data 
are depicted as box (25th to 75th percentiles) and whisker (10th to 90th percentiles), with the 
middle line representing the median. Antigen specificity is depicted according to specific 
colored codes and symbols. Numbers of clones n, as well as Kruskal-Wallis test (α = 0.05) 
derived p values are indicated. Significant differences between the A2/Melan-A26-35- and the 
A2/NY-ESO-1157-165-specific groups were obtained by a Mann Whitney test (two tailed). 
 
 
 
Supplemental Figure 7: Correlations between TCR dissociation rates versus pMHC 
multimer staining versus functional avidity of CD8 T cell clones. (A) Correlations 
between NTAmer-derived TCR dissociation rates (koff), NTAmer surface staining levels 
(gMFI) and killing avidity values (EC50) obtained from independent assays (n = 4 to 9) for 
A2/Melan-A26-35-specific CD8 T cell clones, defined as slow (n = 6, plain symbols) or fast (n 
= 6, empty symbols) TCR off-rates. Each symbol/clone is represented as average ± SD. The 
number of clones (n), as well as Spearman’s correlation (two tailed, α = 0.05) coefficients R 
and p values are indicated. Lines are indicative of linear regression fitting. Representative (B) 
NTAmer-dissociation and (C) killing-titration curves obtained at day 10 (D10), 15 (D15) and 
20 (D20) following non-specific stimulation (by PHA and irradiated feeder cells) of 
A2/Melan-A26-35-specific CD8 T cell clones, defined as slow (n =6, plain symbols and solid 
lines) or fast (n = 6, empty symbols and dotted lines) TCR off-rates. Average and SD 
percentages are depicted, as well as the corresponding fitting curves and koff or EC50 derived 
values. 
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